The W. L. Gore & Associates, Inc. medical business announced that it is initiating the EMBRACE Registry in Europe to evaluate the performance of a new stent.
The registry is being conducted to evaluate the clinical performance and safety of the VBX Stent Graft as a bridging stent. Up to 15 sites in Europe will be required to enroll a minimum of 220 patients that have had treatment with the VBX Stent Graft. The individuals will have follow-up visits up to five years from the initial procedure.
One-year results of the registry are expected mid-2023 and results are intended to be published and presented at major congresses thereafter.
The device was developed utilizing the small diameter, ePTFE stent graft technology from the Gore Viabahn Endoprosthesis.
“Long-term durability and patient outcomes are the cornerstone of our research and development,” said Francisco Barquero, Gore EMEA peripheral sales leader. “This is another step in our continuing efforts to offer the broadest endovascular treatment capabilities on the market.”
For more information about the VBX Stent Graft, visit: goremedical.com/eu/products/vbx
Gore engineers medical devices that treat a range of cardiovascular and other health conditions. Gore has more than 50 million medical devices implanted over more than 45 years.
Gore is headquartered in Newark, with the medical business based in Flagstaff, AZ. The global company has sales of nearly $4 billion.
